InflaRx Announces Participation in September Investor Events
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has announced its participation in two investor conferences in September 2024. The company will attend the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11 in New York, offering an on-demand virtual presentation and one-on-one investor meetings. Additionally, InflaRx will participate in the 2024 Cantor Global Healthcare Conference from September 17-19, featuring a fireside chat on September 18th at 9:45 am ET and investor meetings.
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that has shown promising clinical activity in various indications. The company is also developing INF904, an oral small molecule inhibitor of the C5a receptor.
InflaRx N.V. (Nasdaq: IFRX), una compagnia biofarmaceutica focalizzata su terapie anti-infiammatorie, ha annunciato la sua partecipazione a due conferenze per investitori a settembre 2024. L'azienda sarà presente alla 26a Conferenza Globale sugli Investimenti di H.C. Wainwright dal 9 all'11 settembre a New York, offrendo una presentazione virtuale on-demand e incontri individuali con gli investitori. Inoltre, InflaRx parteciperà alla Conferenza Sanitaria Globale Cantor 2024 dal 17 al 19 settembre, con un incontro a tu per tu il 18 settembre alle 9:45 ET e incontri con gli investitori.
InflaRx è specializzata nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR. Il loro principale candidato prodotto, vilobelimab, è un anticorpo monoclonale anti-C5a somministrato per via intravenosa che ha mostrato una promettente attività clinica in varie indicazioni. L'azienda sta anche sviluppando INF904, un inibitore della piccola molecola orale del recettore C5a.
InflaRx N.V. (Nasdaq: IFRX), una compañía biofarmacéutica centrada en terapias antiinflamatorias, ha anunciado su participación en dos conferencias para inversores en septiembre de 2024. La empresa asistirá a la 26ª Conferencia Global de Inversión de H.C. Wainwright del 9 al 11 de septiembre en Nueva York, ofreciendo una presentación virtual bajo demanda y reuniones individuales con los inversores. Además, InflaRx participará en la Conferencia Global de Salud Cantor 2024 del 17 al 19 de septiembre, con un chat junto a la chimenea el 18 de septiembre a las 9:45 a. m. ET y reuniones con inversores.
InflaRx se especializa en el desarrollo de inhibidores del factor de activación del complemento C5a y su receptor C5aR. Su principal candidato a producto, vilobelimab, es un anticuerpo monoclonal anti-C5a administrado por vía intravenosa que ha mostrado una prometedora actividad clínica en varias indicaciones. La empresa también está desarrollando INF904, un inhibidor de molécula pequeña oral del receptor C5a.
InflaRx N.V. (Nasdaq: IFRX), 항염 치료제에 주력하는 생물제약 회사는 2024년 9월 두 개의 투자자 회의에 참석한다고 발표했습니다. 회사는 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참석하며, 요청 시 가상 프레젠테이션과 개인 투자자 회의를 제공합니다. 또한, InflaRx는 9월 17일부터 19일까지 열리는 2024 Cantor Global Healthcare Conference에 참여하며, 9월 18일 오전 9시 45분 ET에 파이어사이드 채팅과 투자자 회의가 예정되어 있습니다.
InflaRx는 보체 활성화 인자 C5a와 그 수용체 C5aR의 억제제 개발을 전문으로 하고 있습니다. 그들의 주요 제품 후보인 vilobelimab은 정맥 주사로 투여되는 항-C5a 단클론 항체로, 여러 적응증에서 유망한 임상 활성을 보여주었습니다. 회사는 또한 C5a 수용체의 경구용 소분자 억제제인 INF904도 개발하고 있습니다.
InflaRx N.V. (Nasdaq: IFRX), une entreprise biopharmaceutique spécialisée dans les traitements anti-inflammatoires, a annoncé sa participation à deux conférences pour investisseurs en septembre 2024. La société assistera à la 26e Conférence Globale d'Investissement annuelle H.C. Wainwright du 9 au 11 septembre à New York, proposant une présentation virtuelle à la demande et des réunions individuelles avec les investisseurs. De plus, InflaRx participera à la Conférence Mondiale sur la Santé de Cantor 2024 du 17 au 19 septembre, avec une discussion autour d'un feu de cheminée le 18 septembre à 9h45 ET et des réunions avec les investisseurs.
InflaRx se spécialise dans le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR. Leur principal candidat produit, vilobelimab, est un anticorps monoclonal anti-C5a administré par voie intraveineuse, qui a montré une activité clinique prometteuse dans diverses indications. L'entreprise développe également INF904, un inhibiteur oral de petite molécule du récepteur C5a.
InflaRx N.V. (Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapeutika konzentriert, hat seine Teilnahme an zwei Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird von 9. bis 11. September an der 26. jährlichen globalen Investitionskonferenz von H.C. Wainwright in New York teilnehmen und bietet eine virtuelle Präsentation auf Abruf sowie Einzelgespräche mit Investoren an. Darüber hinaus wird InflaRx an der 2024 Cantor Global Healthcare Conference vom 17. bis 19. September teilnehmen, die am 18. September um 9:45 Uhr ET einen Fireside-Chat und Investorenmeetings umfasst.
InflaRx hat sich auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors C5aR spezialisiert. Ihr wichtigster Produktkandidat, vilobelimab, ist ein intravenös verabreichter Anti-C5a-Monoklonaler Antikörper, der in verschiedenen Indikationen vielversprechende klinische Aktivität gezeigt hat. Das Unternehmen entwickelt auch INF904, einen oralen Inhibitor kleiner Moleküle des C5a-Rezeptors.
- Participation in two major investor conferences, potentially increasing visibility and investor interest
- Development of vilobelimab, a lead product candidate with demonstrated clinical activity in multiple indications
- Ongoing development of INF904, an orally administered C5a receptor inhibitor, expanding the company's product pipeline
- None.
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows:
H.C. Wainwright 26th Annual Global Investment Conference
September 9-11, 2024 in New York, NY
InflaRx’s on-demand virtual presentation for the conference will be available beginning on September 9th. InflaRx will also participate in one-on-one investor meetings in New York City on September 10th.
2024 Cantor Global Healthcare Conference
September 17-19, 2024 in New York, NY
InflaRx will conduct a fireside chat at the conference on September 18th at 9:45 am ET and will participate in one-on-one-investor meetings on the same day. A link to register for the fireside chat live stream and its replay is available here.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
What investor events will InflaRx (IFRX) participate in during September 2024?
When is InflaRx's (IFRX) fireside chat at the 2024 Cantor Global Healthcare Conference?
What is InflaRx's (IFRX) lead product candidate?
What technology does InflaRx (IFRX) specialize in?
